Merck Kgaa Dm 5 (MKGAF) 107.6000 $MKGAF Merck KGaA's

New Post Public Reply Private Reply Replies (0) Message Board

Jul 30, 2016 at 11:09 PM

Merck Kgaa Dm 5 (MKGAF) 107.6000 $MKGAF

Merck KGaA's Multiple Sclerosis Drug under Review in EU
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 8:23AM CDT
Merck MGaA (MKGAF) announced that the EMA has accepted to review its MAA for cladribine tablets for the treatment of relapsing-remitting MS.
INVA: 12.87 (+1.17), CYTR: 0.65 (+0.03), NKTR: 17.29 (+1.19)

Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.32 (unch), UTHR: 121.01 (+2.02), PFE: 36.89 (+0.22)

Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 99.42 (+1.22), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15)

Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 14.80 (+0.20), BMRN: 99.42 (+1.22), PFE: 36.89 (+0.22)

Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 1.09 (unch), ANIP: 60.60 (+0.99), XON: 25.33 (+0.62)

Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:20AM CST
Merck KGaA (MKGAF) reported fourth-quarter 2015 earnings of 32 cents, down 60.2% from the year over year.
GILD: 79.47 (-1.77), PFE: 36.89 (+0.22), HZNP: 19.29 (-0.33)

Merck KGaA (MKGAF) Q4 Earnings Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:02AM CST
Merck KGaA (MKGAF) fourth-quarter 2015 earnings per American Depositary Receipt (ADR) came in at 32 cents.

What Awaits Merck KGaA (MKGAF) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:40AM CST
Merck KGaA (MKGAF) will be reporting its fourth-quarter 2015 earnings results on Mar 8.
BDSI: 2.55 (+0.20), BMRN: 99.42 (+1.22), PFE: 36.89 (+0.22)

Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 36.89 (+0.22), HZNP: 19.29 (-0.33), ARNA: 1.67 (-0.01)

Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 8.28 (+0.01), PFE: 36.89 (+0.22), ANIK: 49.92 (+0.70)

Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 8.28 (+0.01), PFE: 36.89 (+0.22), ANIK: 49.92 (+0.70)

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 58.66 (+0.23), PFE: 36.89 (+0.22), CORT: 5.80 (-0.06)

Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 252.95 (-2.61), PFE: 36.89 (+0.22), LLY: 82.89 (-0.04)

Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 25.33 (+0.62), BXLT: 46.02 (-0.18), ANIK: 49.92 (+0.70)

Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 58.66 (+0.23), PFE: 36.89 (+0.22), CORT: 5.80 (-0.06)

Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 17.36 (-0.53), PFE: 36.89 (+0.22), CORT: 5.80 (-0.06)

BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 99.42 (+1.22), NVET: 5.29 (-0.05), REGN: 425.12 (+14.08)

Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 36.89 (+0.22), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)

Merck KGaA Continues Restructuring Efforts, Growth in Focus
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 8:40AM CDT
Merck KGaA (MKGAF) continues with its efforts to simplify the company's organizational structure and focus on the growth trajectory of the Healthcare business.
VRX: 22.30 (-0.83), PFE: 36.89 (+0.22), CORT: 5.80 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Oracle Announces AI-Driven QuickStart Platform Launch

NetSuite's AI-First Step into the Market Well, here's the NYSE stirring the pot with Oracle NetSuite's fresh announcement—an AI-first platform called QuickStart. Sounds like they've got their sights set on early-stage tech startups, banking on those little guys to plug into AI tools they've already got in their toolkit. Claude, ChatGPT—these aren't new kids on the...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

A1 Refrigeration Keeps East Texas Homes Comfortable Year-Round

Homeowners in East Texas would agree: the last thing you want is your HVAC system throwing a tantrum when you're in the thick of a scorching summer or a biting winter. That's where A1 Refrigeration & Air Conditioning steps in, making sure folks in Jasper, Brookeland, and Kirbyville aren't left sweating bullets or shivering in their boots. Preventive Maintenance: A...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....